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practice decisions that involve MH have been poorly understood. We do know that there is a higher prevalence of MH in treated than in nontreated hypertensive subjects, 7 but the mechanism by which antihypertensive treatment is associated with a higher prevalence of MH is not known.
The current International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes (IDACO) study includes a large number of subjects with diabetes mellitus, many of whom have MH-both on and off antihypertensive treatment. These individuals were recruited in communities from 11 countries using standard protocols for conventional blood pressure (CBP) and ambulatory blood pressure (ABP) monitoring, and with a median follow-up of 11 years for cardiovascular events.
We specifically asked the following 2 questions. First, how do the cardiovascular risks in antihypertensive treated versus nontreated diabetics with MH compare with their normotensive comparator groups, stage 1 hypertensives (systolic blood pressure [SBP] 140-159 mm Hg and diastolic blood pressure [DBP] 90-99 mm Hg), and stage 2 hypertensives (SBP ≥160 mm Hg and DBP ≥100 mm Hg), and how do these risk comparisons differ between diabetics and nondiabetics? Second, what are the antihypertensive treatment implications for masked hypertensive diabetics versus those subjects without diabetes mellitus?
Methods

Study Population
At the time of writing this report, the IDACO database 8 included 11 randomly recruited population cohorts [9] [10] [11] [12] [13] [14] [15] [16] [17] and 12 148 participants (for details, see the Expanded Methods in the online-only Data Supplement). We excluded 2457 participants, because they were younger than 18 years (n=303); because their CBP was not on the database (n=248); because they had <10 daytime or 5 nighttime BP readings (n=1905); or because their treatment status at baseline was unknown (n=1). Thus, the total number of subjects included in the present analysis totaled 9691, including 2142 residents from Copenhagen, Denmark 9 ; 1317 inhabitants from Ohasama, Japan 10 ; 1392 subjects from Noorderkempen, Belgium 11 ; 1096 older men from Uppsala, Sweden 12 ; 1438 subjects from Montevideo, Uruguay 13 ; 349 villagers from the JingNing county, China 14 ; 244 subjects from Novosibirsk, the Russian Federation 15 ; 165 from Pilsen, Czech Republic 16 ; 930 from Dublin, Ireland 17 ; 310 from Padua, Italy 16 ; and 308 from Kraków, Poland ( Figure 1 ). 16 
BP Measurement
Methods used for CBP and ABP measurements are described in detail in the Expanded Methods. CBP was the average of 2 consecutive readings obtained either at the person's home, 11, [13] [14] [15] [16] or at an examination center. 10, 12, 17, 18 Portable monitors were programmed to obtain ABP readings at 30-minute intervals throughout the whole day, 10, 17 or at intervals ranging from 15 18 to 30 12 minutes during daytime and from 30 18 to 60 12 minutes at night. We categorized the CBP according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
19 guidelines. Normotension was a level <140 mm Hg systolic and <90 mm Hg diastolic. Stage 1 hypertension encompassed 140 to 159 mm Hg systolic or 90 to 99 mm Hg diastolic. CBP of at least 160 mm Hg systolic or 100 mm Hg diastolic was classified as stage 2 hypertension. Ambulatory hypertension was a daytime ABP of 135 mm Hg systolic or 85 mm Hg diastolic or more. 20 Sustained normotension was normotension on both CBP and ABP measurement. Masked hypertension was ambulatory hypertension in participants with a normal CBP. Patients on antihypertensive drug treatment were classified according to their treated BP. The term normotension in treated subjects refers to successfully treated hypertensive patients; that is, hypertensive subjects whose BP, both CBP and ABP, are controlled on antihypertensive drug therapy.
Other Measurements
We used the questionnaires originally administered in each cohort to obtain information on each participant's medical history and smoking and drinking habits. Diabetes mellitus was the use of antidiabetic drugs, [9] [10] [11] [12] [13] [14] [15] [16] a fasting blood glucose concentration of at least 7.0 mmol/L, [9] [10] [11] [12] [13] [14] [15] [16] a random blood glucose concentration of at least 11.1 mmol/L, 10,11,14-16 a self-reported diagnosis, 11, [13] [14] [15] [16] [17] or diabetes mellitus documented in practice or hospital records. 13 Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease study equation. 
Ascertainment of Events
The composite cardiovascular end point included fatal and nonfatal stroke, transient ischemic attacks, death from ischemic heart disease, sudden death, nonfatal myocardial infarction, angina pectoris, coronary revascularization, fatal and nonfatal heart failure, and fatal and nonfatal peripheral arterial disease. A restricted definition of the composite cardiovascular end point not including transient ischemic attacks, angina pectoris, and nonfatal peripheral arterial disease was used for sensitivity analyses. In all outcome analyses, we only considered the first event within each category.
Statistical Analysis
For database management and statistical analysis, we used SAS software, version 9.3 (SAS Institute, Cary, NC). For comparison of means and proportions, we applied the large-sample z-test and the χ 2 statistic, respectively. The risk association with MH was assessed using Cox regression analysis, stratified for cohort, and adjusted for sex, age, body mass index, smoking and drinking, serum cholesterol, and history of cardiovascular complications. We compared hazard ratios between groups by testing the significance of the appropriate interaction term. Statistical significance was an α-level of <0.05 on 2-sided tests.
Results
Baseline Characteristics
As shown in the flow chart, 9691 participants were included in the analysis (Figure 1 On CBP measurement 6432 (66.4%) participants were normotensive, and 2196 (22.7%) and 1063 (11.0%) had stage 1 or stage 2 hypertension. Of the 6432 subjects with conventional normotension, 1327 (20.6%) had MH. The characteristics of the untreated and treated study participants by BP status and the presence or absence of diabetes mellitus are shown in Table 1 and Table S1 in the online-only Data Supplement.
Prevalence of Masked Hypertension in Subjects With and Without Diabetes Mellitus
The prevalence of MH in untreated participants normotensive on CBP measurement was higher (P<0.0001) among the 229 diabetics (29.3%, n=67) than among the 5486 nondiabetics (18.8%, n=1031). The sex-and age-adjusted odds ratio for untreated MH in diabetics versus nondiabetics was 1 
Risk Associated With Masked Hypertension and Diabetes Mellitus
In the overall study population, the median follow-up was 11.0 years (5th to 95th percentile interval, 2.5-18.1 years). During 106 087 person-years of follow-up, 1412 subjects experienced a fatal or nonfatal cardiovascular complication (14.0 per 1000 person-years). The risks associated with MH in untreated and treated nondiabetics and diabetics are illustrated in Figure 2 (adjusted for cohort, sex, and age only) and in Figure 3 (full adjustment).
The diabetic subjects not receiving antihypertensive treatment included 162 sustained normotensives, 67 masked hypertensives, 93 stage 1 hypertensives, and 47 stage 2 hypertensives; within these 4 groups, the numbers of cardiovascular events were as follows: 14 (7. Figure S2 shows the association between the daytime and conventional SBP and DBP in untreated and treated diabetic subjects with MH. In the 67 diabetic subjects with untreated MH, the 5th to 95th percentile interval of the CBP ranged from 112 to 139 mm Hg systolic and from 65 to 88 mm Hg diastolic.
ABP Versus CBP in Diabetic Subjects With Masked Hypertension
Discussion
There were 2 important findings in this 11-country IDACO study. First, 42.5% of the antihypertensive-treated diabetics with normalized CBP had an on-treatment daytime ABP within the hypertensive range. These presumed masked hypertensive subjects had similar cardiovascular risk as treated subjects with sustained normotension and those with uncontrolled stage 1 and stage 2 hypertension. Second, the untreated masked hypertensive diabetic population represented 29.3% of the normotensive CBP population, showed greater risk than those with sustained normotension, showed equivalent cardiovascular risk to a stage 1 diabetic population, but less risk as compared with stage 2 hypertension. Although untreated and treated diabetics were at higher risk than the untreated and treated nondiabetics, respectively, the HRs comparing the risk in the various BP categories were similar in diabetics and nondiabetics.
Cardiovascular Risk in Antihypertensive-Treated Subjects With Masked Hypertension
When Pickering first coined the term MH in 2002, 22 he was referring to untreated subjects with elevated ABP in the presence of normal CBP. When dealing with a population that has received antihypertensive therapy, the normotensive comparator group may be at increased risk, as we have shown to be true when evaluating treated whitecoat hypertension. 23 The same relation applies to treated hypertension in general, 24 and specifically to MH. Indeed, the present study showed that the antihypertensive-treated Masked HT, n=1031
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diabetics with presumed MH were at the same cardiovascular risk as the comparator group with normalized CBP and ABP, whereas untreated diabetic subjects with MH tended to have higher cardiovascular risk than their sustained normotensive comparator group.
Sustained Hypertensives Undergoing Antihypertensive Treatment may Mimic Masked Hypertension
There is abundant evidence from previous studies that antihypertensive treatment will lower ABP values by only 60% to 70% of the reduction in CBP pressures, that is, approximately a 3-mm Hg SBP reduction of CBP for a 2-mm Hg SBP reduction of ABP. [25] [26] [27] The findings in the present study are consistent with this treatment effect: the prevalence of MH in the normotensive diabetic population receiving antihypertensive therapy was 42.5% and in those who were untreated was 29.3%; thus, there was an approximate ratio of 1.5 to1.0 (or 3 to 2), comparing the prevalence of treated with untreated MH in the diabetic population. Our working hypothesis is that a significant number of subjects with diabetic MH actually had sustained hypertension before beginning antihypertensive therapy; with therapy, they normalized CBP but continued to have elevated ABP values, and thus mimicked MH. Indeed, if antihypertensive treatment would have equally reduced systolic CBP and ABP, the untreated and treated diabetic MH prevalence would be equal. In summary, this is the first study, to our knowledge, to show that antihypertensive-treated diabetics can present with normalized CBP and elevated ABP that mimics MH; in reality, many of these subjects were sustained hypertensives masquerading as MH.
Patient compliance with treatment and/or adequacy of antihypertensive therapy by the physician may have a direct affect on the prevalence of MH. The presence of effective antihypertensive therapy may (1) in large part normalize both CBP and ABP, and present as optimally treated BP, so that MH is greatly reduced or totally eliminated. More commonly, insufficient antihypertensive therapy may (2) in large part normalize CBP, whereas ABP remains elevated, suggesting that a significant number of untreated sustained hypertensives were converted to treated MH; this results in a particularly high prevalence of MH. Because the prevalence of MH is higher in treated versus untreated diabetics (and nondiabetics), as noted in the current study and generally as noted in the literature, [28] [29] [30] this suggests that a large number of physicians that treat hypertensive diabetics (or nondiabetics) erroneously focus primarily on normalizing CBP rather than monitoring for normalization of ABP or home BP.
Antihypertensive Treatment Goals for Diabetics With Masked Hypertension
Previous studies have shown that diabetic subjects have not only a high prevalence of MH, 31, 32 but also high rates of target organ damage 33, 34 and a cardiovascular risk profile similar to sustained hypertension, so that out-of-office BP monitoring 35, 36 and antihypertensive therapy can be justified in subjects with these characteristics. Furthermore, not only the present study, but also a previous IDACO publication have shown that the cardiovascular risk is the summation of the risk of diabetes mellitus plus the risk of hypertension. 37 In the present study, diabetic subjects with untreated MH had a mean CBP of 129.2/76.0 mm Hg (with values that ranged as low as 110/60 mm Hg) and corresponding mean daytime ABP of 141.5/83.7 mm Hg. Therefore, if the primary treatment strategy is reaching daytime ABP treatment target goal, this would inevitably lead to further reduction in CBP values.
Tight BP control (systolic CBP <130 mm Hg and diastolic CBP <80 mm Hg) appears to be applicable for reduction in stroke events, in young diabetics, and in diabetics of shortduration. In contrast, usual BP control (systolic CBP <140 mm Hg and diastolic CBP <90 mm Hg) appears to be more applicable to reduction of ischemic heart disease events 
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and in older and longer-duration diabetics. [38] [39] [40] Importantly, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, the largest of the intervention studies that compared intense with usual care reduction in BP control in hypertensive diabetics, did not recruit subjects with MH specifically. 41 Therefore, at the present time, there are no credible outcome studies in diabetics with MH to prove the benefit of antihypertensive therapy or to indicate how low to go with the reduction in daytime and nighttime ABP to achieve optimal reduction in cardiovascular risk. Furthermore, any significant reduction in ABP would be associated with even larger reductions in CBP values, which are already lower than JNC7 recommended guidelines. 19 Thus, there is the possibility that with antihypertensive treatment in diabetic subjects with MH, one may have to balance the increased cardiovascular risk of lower diastolic CBP and ABP values with the potential benefit of further reduction in systolic CBP and ABP values. 42 
Strengths and Limitations
Our study must be interpreted within the context of its strengths and potential limitations. First, the CBP was measured under differing conditions in the cohorts. However, in all but 1 cohort, BP was measured in the sitting position, and in all cohorts, the average of only 2 CBP measurements was used for analysis. In addition, all of the cohorts implemented rigorous quality control programs for BP measurement. Second, ABP monitoring was not standardized in terms of device type and intervals between successive readings. However, all ABP means were weighted for the interval between successive readings. By design, this meta-analysis was based on data from individuals, rather than from aggregate data from each individual study. Third, the analysis rested on 11 populationbased cohorts over 3 continents with an overrepresentation of European subjects, and might therefore not be representative for other ethnic groups, in particular blacks. Fourth, the confidence intervals around the hazard ratios comparing the risks in masked hypertensives versus normotensives and stage 1 and stage 2 hypertensives were wide, reflecting limited statistical power to accurately assess differences between these subgroups. Finally, a possible limitation of the study is the question of reproducibility of MH. However, generally, high reproducibility have been shown in adults with MH in previous studies. 
Perspectives
Using the 11-country IDACO population database and measuring CBP and 24-hour ABP, we noted a higher prevalence of MH in diabetics than nondiabetics; this finding was more prominent in treated versus nontreated diabetics. Of significance, cardiovascular risk in diabetics not receiving antihypertensive treatment and presenting with MH was significantly greater than in their normotensive comparator group and was equivalent to the risk in diabetics with stage 1 hypertension. In contrast, antihypertensive-treated diabetics with MH on 24-hour ABP monitoring had cardiovascular risk that was equal to treated normotensives and stage 1 and stage 2 hypertensive subjects, strongly suggesting that a significant percentage of these subjects had sustained hypertension that mimicked MH in the presence of normalized CBP and elevated ABP. Hence, the term MH should be used with caution in the presence of antihypertensive therapy. Furthermore, because antihypertensive therapy always decreases CBP more than ABP, there is the danger that reliance on CBP as target treatment goal will result in suboptimal control of BP in subjects with either sustained hypertension or MH; thus, out-of-office BP monitoring should be used to focus on home and/or ABP target goals in both diabetics and nondiabetics. Unfortunately, there are no specific treatment guidelines based on randomized controlled trials in either diabetic or nondiabetic subjects with MH or sustained hypertension masquerading as MH, so that antihypertensive treatment goals remain empirical.
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Expanded Methods
Study Population
As described in detail elsewhere, 1 we constructed the International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO). Studies were eligible for inclusion, if they involved a random population sample, if baseline information on the ambulatory blood pressure and cardiovascular risk factors was available, and if the subsequent follow-up included both fatal and nonfatal outcomes. All participants gave informed written consent. Subjects recruited in Kraków, Novosibirsk, Pilsen, and Padova took part in the European Project on Genes in Hypertension (EPOGH). 2
Blood Pressure Measurements
Conventional blood pressure was measured by trained observers with a mercury sphygmomanometer, [2] [3] [4] [5] [6] [7] [8] with validated auscultatory 9 (USM-700F, UEDA Electronic Works, Tokyo, Japan) or oscillometric 10 (OMRON HEM-705CP, Omron Corporation, Tokyo, Japan) devices, using the appropriate cuff size, with participants in the sitting 2,3,5-10 or supine 4 position. Conventional blood pressure was the average of 2 consecutive readings obtained either at the person's home 2, 5, 6, 8, 10 or at an examination center. 3, 4, 7, 9 We programmed portable monitors to obtain ambulatory blood pressure readings at 30 minute intervals throughout the whole day, 7, 9 or at intervals ranging from 15 3 The same SAS progam processed all ambulatory recordings, which generally stayed unedited. The Ohasama recordings were edited sparsely according to previously published criteria. 11 Within individual subjects, we weighted the means of the ambulatory blood pressure by the interval between readings. When accounting for the daily pattern of activities of the participants, we defined daytime as the interval ranging from 1000 h to 2000 h in people from Europe [2] [3] [4] [5] 7, 8 and South America, 10 and from 0800 h to 1800 h in those from Asia. 6, 9 The corresponding night-time intervals ranged from midnight to 0600 h [2] [3] [4] [5] 7, 8, 10 and from 2200 h to 0400 h. 6, 9 These fixed intervals eliminate the transition periods in the morning and evening when blood pressure changes rapidly, resulting in daytime and night-time blood pressure levels that are within 1-2 mm Hg of the awake and asleep levels. 6, 12 We categorized the conventional blood pressure according to the JNC7 13 guidelines. Normotension was a level lower than 140 mm Hg systolic and 90 mm Hg diastolic. Stage 1 hypertension encompassed 140 to 159 mm Hg systolic or 90 to 99 mm Hg diastolic. Conventional blood pressures of at least 160 mm Hg systolic or 100 mm Hg diastolic were classified as stage 2 hypertension. Ambulatory hypertension was a daytime blood pressure of 135 mm Hg systolic or 85 mm Hg diastolic or more. 14 Sustained normotension was normotension on both conventional and ambulatory measurement. Masked hypertension was ambulatory hypertension in participants with a normal conventional blood pressure. Patients on antihypertensive drug treatment were classified according to their treated blood pressure. The term 'normotension' in treated subjects refer to successfully treated hypertensive patients, i.e. hypertensive subjects whose blood pressure, both CBP and ABP, are controlled on antihypertensive drug therapy.
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Other Measurements
We used the questionnaires originally administered in each cohort to obtain information on each participant's medical history and smoking and drinking habits. Body mass index was body weight in kilograms divided by height in meters squared. We measured serum cholesterol and blood glucose by automated enzymatic methods. Diabetes mellitus was the use of antidiabetic drugs, 2,4-6,8-10,15 , a fasting blood glucose concentration of at least 7.0 mmol/L, 2,4-6,8-10,15 a random blood glucose concentration of at least 11.1 mmol/L, 2,5,6,8,9 a self-reported diagnosis, 2, [5] [6] [7] [8] 10 or diabetes documented in practice or hospital records. 10 To measure the serum creatinine concentration, all laboratories applied Jaffe's method 16 with the modifications described elsewhere 17, 18 to overcome interferences and limitations. The samples were run on automated analyzers in certified laboratories that participated in external quality control programs. We used the Modification of Diet in Renal Disease (MDRD) Study equation 19 to estimate the glomerular filtration rate (GFR) from sex, age, and the serum creatinine concentration.
Ascertainment of Events
We ascertained vital status and the incidence of fatal and nonfatal diseases from the appropriate sources in each country, as described in previous publications. [20] [21] [22] The composite cardiovascular endpoint included fatal and non-fatal stroke, transient ischemic attacks, death from ischemic heart disease, sudden death, nonfatal myocardial infarction, angina pectoris, coronary revascularization, fatal and non-fatal heart failure and fatal and non-fatal peripheral arterial disease. A restricted definition of the composite cardiovascular endpoint not including transient ischemic attacks, angina pectoris and non-fatal peripheral arterial disease, was used for sensitivity analyses. In the Danish 15 and Swedisch cohorts, 4 the diagnosis of heart failure required hospitalization. In the Uruguayan cohort 10 the diagnosis of heart failure required dyspnea and a left ventricular ejection fraction of less than 40%. In the other cohorts, 2,5-9 heart failure was either a clinical diagnosis or the diagnosis on the death certificate, but in all cases, validated against hospital records or the records held by general practitioners. In all outcome analyses, we only considered the first event within each category.
Statistical Analysis
For database management and statistical analysis, we used SAS software, version 9.3 (SAS Institute, Cary, NC). For comparison of means and proportions, we applied the large-sample z-test and the χ 2 -statistic, respectively. The risk association with masked hypertension was assessed using Cox regression analysis, stratified for cohort and adjusted for for sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular complications, and diabetes mellitus. To stratify for cohort, we pooled participants recruited in the framework of the European Project on Genes in Hypertension (Kraków, Novosibirsk, Padova, and Pilsen). We ascertained that the proportional hazard assumption underlying the Cox regression models was fulfilled by testing the interaction between the BP categories and follow-up time. We compared hazard ratios between groups by testing the significance of the appropriated interaction term. Statistical significance was an α-level of less than 0.05 on two-sided tests. Figure S2 . Association between the daytime and conventional blood pressures in 67 untreated (left panels) and 37 treated (right panels) diabetic subjects with masked hypertension. The upper panels show the systolic blood pressures (SBP); the lower panels the diastolic blood pressures (DBP). The regression lines, 95% confidence bands of the mean, Pearson correlation coefficients (r) and corresponding P-values are provided.
